MedTrace Logo

The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

NCT06691061 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2024-11-15

No results posted yet for this study

Summary

The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.

Conditions

  • Ulcerative Colitis (Disorder)

Interventions

DRUG

Vedolizumab

UC patients treated with vedolizumab

DRUG

Ustekinumab - Standard Dosage

UC patients treated with ustekinumab

DRUG

JAK Inhibitor

UC patients treated with JAK inhibitors

Sponsors & Collaborators

  • Humanitas Clinical and Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06691061 on ClinicalTrials.gov